Revance Therapeutics Inc (FRA:RTI)
€ 3.4 -0.1 (-2.86%) Market Cap: 371.12 Mil Enterprise Value: 655.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Q3 2021 Revance Therapeutics Inc Earnings Call Transcript

Nov 09, 2021 / 09:30PM GMT
Release Date Price: €11.8 (-2.48%)
Operator

Welcome to Revance Therapeutics Third Quarter 2021 Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded today, 9th of November 2021.

I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG of Revance. Please go ahead.

Jessica Serra
Revance Therapeutics, Inc. - Head of IR & ESG

Thank you, Laurie. Joining us on the call today from Revance, our Chief Executive Officer, Mark Foley; President, Dustin Sjuts; Chief Financial Officer, Toby Schilke; and Senior Vice President of Clinical Development, Roman Rubio.

During this conference call, management will make forward-looking statements, including statements related to the potential approval and timing of approval of DaxibotulinumtoxinA for Injection in glabellar lines and therapeutic indications; our ability to remediate deficiencies identified by the FDA regarding our BLA; a Type A meeting with the FDA; financial performance, revenue and processing volume run rate; financial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot